Present and Future Medical Applications of Microbial Exopolysaccharides

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2015 Oct 21

PMID 26483763

Citations 65

Authors

Misu Moscovici

Affiliations

Soon will be listed here.

Abstract

Microbial exopolysaccharides (EPS) have found outstanding medical applications since the mid-20th century, with the first clinical trials on dextran solutions as plasma expanders. Other EPS entered medicine firstly as conventional pharmaceutical excipients (e.g., xanthan - as suspension stabilizer, or pullulan - in capsules and oral care products). Polysaccharides, initially obtained from plant or animal sources, became easily available for a wide range of applications, especially when they were commercially produced by microbial fermentation. Alginates are used as anti-reflux, dental impressions, or as matrix for tablets. Hyaluronic acid and derivatives are used in surgery, arthritis treatment, or wound healing. Bacterial cellulose is applied in wound dressings or scaffolds for tissue engineering. The development of drug controlled-release systems and of micro- and nanoparticulated ones, has opened a new era of medical applications for biopolymers. EPS and their derivatives are well-suited potentially non-toxic, biodegradable drug carriers. Such systems concern rating and targeting of controlled release. Their large area of applications is explained by the available manifold series of derivatives, whose useful properties can be thereby controlled. From matrix inclusion to conjugates, different systems have been designed to solubilize, and to assure stable transport in the body, target accumulation and variable rate-release of a drug substance. From controlled drug delivery, EPS potential applications expanded to vaccine adjuvants and diagnostic imaging systems. Other potential applications are related to the bioactive (immunomodulator, antitumor, antiviral) characteristics of EPS. The numerous potential applications still wait to be developed into commercial pharmaceuticals and medical devices. Based on previous and recent results in important medical-pharmaceutical domains, one can undoubtedly state that EPS medical applications have a broad future ahead.

Citing Articles

Statistical optimisation and analysis of biomass and exopolysaccharide production by Lacticaseibacillus rhamnosus LRH30.

Copeland H, Maye S, MacLeod G, Brabazon D, Loscher C, Freeland B World J Microbiol Biotechnol. 2025; 41(2):58.

PMID: 39888560 PMC: 11785610. DOI: 10.1007/s11274-025-04273-2.

Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.

Afkhami H, Yarahmadi A, Bostani S, Yarian N, Haddad M, Lesani S Discov Oncol. 2024; 15(1):818.

PMID: 39707033 PMC: 11662135. DOI: 10.1007/s12672-024-01590-0.

Advances in Microbial Exopolysaccharides: Present and Future Applications.

Nguyen H, Pham T, Nguyen P, Le-Buanec H, Rabetafika H, Razafindralambo H Biomolecules. 2024; 14(9).

PMID: 39334928 PMC: 11430787. DOI: 10.3390/biom14091162.

Microbial extracellular polymeric substances in the environment, technology and medicine.

Flemming H, van Hullebusch E, Little B, Neu T, Nielsen P, Seviour T Nat Rev Microbiol. 2024; 23(2):87-105.

PMID: 39333414 DOI: 10.1038/s41579-024-01098-y.

Health Benefits and Safety of Postbiotics Derived from Different Probiotic Species.

Harat S, Pourjafar H Curr Pharm Des. 2024; 31(2):116-127.

PMID: 39297457 DOI: 10.2174/0113816128335414240828105229.

References

Jiang L, Li X, Liu L, Zhang Q . Cellular uptake mechanism and intracellular fate of hydrophobically modified pullulan nanoparticles. Int J Nanomedicine. 2013; 8:1825-34. PMC: 3652563. DOI: 10.2147/IJN.S44342. View

Lee M, Yang J, Jung H, Beack S, Choi J, Hur W . Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection. ACS Nano. 2012; 6(11):9522-31. DOI: 10.1021/nn302538y. View

DArrigo G, Navarro G, Di Meo C, Matricardi P, Torchilin V . Gellan gum nanohydrogel containing anti-inflammatory and anti-cancer drugs: a multi-drug delivery system for a combination therapy in cancer treatment. Eur J Pharm Biopharm. 2013; 87(1):208-16. DOI: 10.1016/j.ejpb.2013.11.001. View

Fu L, Zhang J, Yang G . Present status and applications of bacterial cellulose-based materials for skin tissue repair. Carbohydr Polym. 2013; 92(2):1432-42. DOI: 10.1016/j.carbpol.2012.10.071. View

Park M, Lee D, Hyun J . Nanocellulose-alginate hydrogel for cell encapsulation. Carbohydr Polym. 2014; 116:223-8. DOI: 10.1016/j.carbpol.2014.07.059. View

Freitas F, Alves V, Reis M . Advances in bacterial exopolysaccharides: from production to biotechnological applications. Trends Biotechnol. 2011; 29(8):388-98. DOI: 10.1016/j.tibtech.2011.03.008. View

Ohno N, Suzuki I, Yadomae T . Structure and antitumor activity of a beta-1,3-glucan isolated from the culture filtrate of Sclerotinia sclerotiorum IFO 9395. Chem Pharm Bull (Tokyo). 1986; 34(3):1362-5. DOI: 10.1248/cpb.34.1362. View

Prajapati V, Jani G, Khanda S . Pullulan: an exopolysaccharide and its various applications. Carbohydr Polym. 2013; 95(1):540-9. DOI: 10.1016/j.carbpol.2013.02.082. View

da Cunha M, Turmina J, Ivanov R, Barroso R, Marques P, Fonseca E . Lasiodiplodan, an exocellular (1→6)-β-D: -glucan from Lasiodiplodia theobromae MMPI: production on glucose, fermentation kinetics, rheology and anti-proliferative activity. J Ind Microbiol Biotechnol. 2012; 39(8):1179-88. DOI: 10.1007/s10295-012-1112-2. View

10.

Gao F, Li L, Zhang H, Yang W, Chen H, Zhou J . Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies. Int J Pharm. 2010; 392(1-2):254-60. DOI: 10.1016/j.ijpharm.2010.03.044. View

11.

Saldias C, Velasquez L, Quezada C, Leiva A . Physicochemical assessment of dextran-g-poly (ɛ-caprolactone) micellar nanoaggregates as drug nanocarriers. Carbohydr Polym. 2014; 117:458-467. DOI: 10.1016/j.carbpol.2014.09.035. View

12.

Nwodo U, Green E, Okoh A . Bacterial exopolysaccharides: functionality and prospects. Int J Mol Sci. 2012; 13(11):14002-15. PMC: 3509562. DOI: 10.3390/ijms131114002. View

13.

Zong A, Cao H, Wang F . Anticancer polysaccharides from natural resources: a review of recent research. Carbohydr Polym. 2012; 90(4):1395-410. DOI: 10.1016/j.carbpol.2012.07.026. View

14.

Gupta M, Gupta A . Hydrogel pullulan nanoparticles encapsulating pBUDLacZ plasmid as an efficient gene delivery carrier. J Control Release. 2004; 99(1):157-66. DOI: 10.1016/j.jconrel.2004.06.016. View

15.

Tran T, Choi J, Ramasamy T, Truong D, Nguyen C, Choi H . Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polym. 2014; 114:407-415. DOI: 10.1016/j.carbpol.2014.08.026. View

16.

Hongpattarakere T, Cherntong N, Wichienchot S, Kolida S, Rastall R . In vitro prebiotic evaluation of exopolysaccharides produced by marine isolated lactic acid bacteria. Carbohydr Polym. 2021; 87(1):846-852. DOI: 10.1016/j.carbpol.2011.08.085. View

17.

Notararigo S, de Las Casas-Engel M, de Palencia P, Corbi A, Lopez P . Immunomodulation of human macrophages and myeloid cells by 2-substituted (1-3)-β-D-glucan from P. parvulus 2.6. Carbohydr Polym. 2014; 112:109-13. DOI: 10.1016/j.carbpol.2014.05.073. View

18.

Matsuda , Shigeta , Okutani . Antiviral Activities of Marine Pseudomonas Polysaccharides and Their Oversulfated Derivatives. Mar Biotechnol (NY). 1999; 1(1):68-73. DOI: 10.1007/pl00011753. View

19.

Coseri S, Spatareanu A, Sacarescu L, Rimbu C, Suteu D, Spirk S . Green synthesis of the silver nanoparticles mediated by pullulan and 6-carboxypullulan. Carbohydr Polym. 2014; 116:9-17. DOI: 10.1016/j.carbpol.2014.06.008. View

20.

Tassa C, Shaw S, Weissleder R . Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011; 44(10):842-52. PMC: 3182289. DOI: 10.1021/ar200084x. View